Axsome Therapeutics (AXSM) Equity Average: 2022-2025
Historic Equity Average for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $73.4 million.
- Axsome Therapeutics' Equity Average fell 25.01% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year decrease of 25.01%. This contributed to the annual value of $124.0 million for FY2024, which is 17.48% down from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Equity Average is $73.4 million, which was up 16.25% from $63.1 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Equity Average registered a high of $274.2 million during Q3 2023, and its lowest value of $14.9 million during Q2 2022.
- In the last 3 years, Axsome Therapeutics' Equity Average had a median value of $110.7 million in 2023 and averaged $133.3 million.
- As far as peak fluctuations go, Axsome Therapeutics' Equity Average surged by 1,206.52% in 2023, and later tumbled by 67.44% in 2024.
- Over the past 4 years, Axsome Therapeutics' Equity Average (Quarterly) stood at $133.5 million in 2022, then surged by 72.52% to $230.2 million in 2023, then plummeted by 67.44% to $75.0 million in 2024, then declined by 25.01% to $73.4 million in 2025.
- Its last three reported values are $73.4 million in Q3 2025, $63.1 million for Q2 2025, and $55.1 million during Q1 2025.